Inflammatory Bowel Diseases Clinical Trial
Official title:
Pre-operative Nutrition for Elective Resection Surgery in Inflammatory Bowel Disease
This study aims to determine if improved risk stratification tools and interventions to mitigate malnutrition reduce postoperative risk in patients undergoing elective or emergent resection surgery for inflammatory bowel disease (IBD), and if adding immune modulation nutrition improves surgical outcomes. The primary objective is to assess whether preoperative malnutrition screening and intervention minimize postoperative complications. The secondary objective is to evaluate whether immune modulation nutrition in the peri-operative period decreases length of stay and major complications.
Status | Not yet recruiting |
Enrollment | 150 |
Est. completion date | April 2025 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Able and willing to provide written informed consent 2. Aged 18 years of age or older 3. Confirmed diagnosis of inflammatory bowel disease 4. Scheduled for disease-related intestinal resection at NYU Langone Health Exclusion Criteria: 1. No current diagnosis of inflammatory bowel disease 2. Age less than 18 3. Not proficient (able to read and answer questions) in English |
Country | Name | City | State |
---|---|---|---|
United States | NYU Langone Health | New York | New York |
Lead Sponsor | Collaborator |
---|---|
NYU Langone Health |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Length of hospital stay | From the time the patient is admitted at hospital for surgery until the patient is discharged. | Up to 30 days post-surgery | |
Primary | Proportion of patients who experienced postoperative major complications | Major complications include infection, bleeding (requiring blood transfusion or requiring intervention), cardiac event (myocardial infarction, arrhythmia, and cardiac arrest), stroke, acute kidney injury (increase in serum creatinine of =0.3 mg/dL from baseline or =1.5 times baseline), venous thromboembolism, reoperation, readmission, and need for ICU-level care. The outcome measure will be obtained from the electronic health record (EHR). | Visit 3 (30 days post-surgery) | |
Secondary | Proportion of patients who participated in a nutritional intervention program before surgery | Visit 3 (30 days post-surgery) | ||
Secondary | Proportion of patients who participated in a nutritional intervention program after surgery | Visit 3 (30 days post-surgery) | ||
Secondary | Number of nutritional shakes completed | Visit 3 (30 days post-surgery) | ||
Secondary | Percentage of nutritional shakes completed overall | Visit 3 (30 days post-surgery) | ||
Secondary | Percentage of nutritional shakes completed pre-surgery | Subject will be called the day prior to surgery to determine the number of shakes consumed by patient. | One day prior to surgery | |
Secondary | Percentage of nutritional shakes completed post-surgery | One week after surgery, a phone call will follow to determine how many shakes subject consumed. | One week post surgery | |
Secondary | Proportion of patients who experienced any postoperative complications | Visit 3 (30 days post-surgery) | ||
Secondary | Proportion of patients with 30 day readmission | Up to 30 days post-surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04046913 -
The ADDapt Diet in Reducing Crohn's Disease Inflammation
|
N/A | |
Active, not recruiting |
NCT04989907 -
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Active, not recruiting |
NCT04990258 -
A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
|
||
Completed |
NCT06216223 -
Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients
|
N/A | |
Enrolling by invitation |
NCT06015789 -
Self-care in Patients Affected by Inflammatory Bowel Disease and Caregivers' Contribution to Self-care
|
||
Recruiting |
NCT06065995 -
StoMakker Mobile Application
|
N/A | |
Recruiting |
NCT03282786 -
Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease
|
N/A | |
Recruiting |
NCT06002074 -
SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT04960826 -
Study of an Environmental Risk Factor in Crohn's Disease
|
||
Recruiting |
NCT05413941 -
Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease
|
N/A | |
Completed |
NCT03668249 -
A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
|
||
Completed |
NCT00721812 -
A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686
|
Phase 1 | |
Recruiting |
NCT05809999 -
IBD Neoplasia Surveillance RCT
|
N/A | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Recruiting |
NCT04991324 -
Cholecalciferol Comedication in IBD - the 5C-study
|
Phase 3 | |
Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
Not yet recruiting |
NCT05043818 -
A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
|
||
Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
Completed |
NCT02874365 -
Intestinal Stem Cells Characterization
|
N/A |